The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $148.00. The company’s shares clos ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Chicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS. Industry: Generic Drugs.

Amgen remains a top contender for value investors looking to buy quality at a discount. The biotech giant boasts a Value ...

Today, Benzinga's options scanner spotted 13 options trades for Amgen. This is not a typical pattern. The sentiment among ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Amgen is cruising through Wall Street like it just hit cruise control, earning a consensus "Hold" rating from 24 analysts.

Complete Amgen Inc. stock information by Barron's. View real-time AMGN stock price and news, along with industry-best analysis.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...